Back

Investigating monotherapy and combination therapy trends in newly diagnosed patients with pulmonary arterial hypertension among EU3 & UK physicians over the COVID-19 pandemic.

26 August 2022 (12:15 - 12:40)
Organised by:
Congress Presentation Part of: Focus on the pulmonary vascular bed Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Dale Chandler

Ipsos, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial
Doctor P. Clift (Birmingham, GB)
Abstract Slides
Presentation thumbnail
Ventricular-arterial coupling predicts outcomes in adults with a systemic right ventricle
Doctor G. Pasqualin (Milan, IT)
Abstract Slides
Presentation thumbnail
Inactivation of catalytic and non-catalytic PI3 kinase gamma functions enhances hypoxia-induced pulmonary hypertension in mice
Mrs L. Gnatzy-Feik (Cologne, DE)
Abstract Slides
Presentation thumbnail
Efficacy and safety of selexipag in real-life in patients with pulmonary arterial hypertension: early results of RAMPHA study
Doctor R. Bravo-Marques (Marbella, ES)
Abstract Slides

Access the full session

Session thumbnail
Focus on the pulmonary vascular bed

The Event

Event poster

ESC Congress 2022

26 August 2022 12:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources